Fresenius SE & Co. KGaA (FRA:FRE)

Market Cap	24.62B +9.5%
Revenue (ttm)	22.87B +4.5%
Net Income	1.26B
EPS	2.24
Shares Out	n/a
PE Ratio	19.48
Forward PE	12.03
Dividend	1.00 (2.28%)
Ex-Dividend Date	May 26, 2025

Volume	2,179
Average Volume	2,492
Open	43.96
Previous Close	44.29
Day's Range	43.78 - 43.99
52-Week Range	32.43 - 52.84
Beta	n/a
RSI	33.17
Earnings Date	May 6, 2026

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition prod...

• Industry: Miscellaneous Health And Allied Services, Not Elsewhere Classified
• Founded: 1912
• Employees: 177,356
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: FRE

Financial Performance

In 2025, Fresenius SE & Co. KGaA's revenue was 22.87 billion, an increase of 4.19% compared to the previous year's 21.95 billion. Earnings were 1.26 billion, an increase of 168.37%.